Teva Pharmaceutical Industries (TEVA) Short term Debt (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Short term Debt for 18 consecutive years, with $4.5 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Short term Debt rose 869.83% year-over-year to $4.5 billion; the trailing twelve-month figure through Jun 2026 stood at $4.5 billion (up 869.83% YoY), and the FY2025 full-year result was $1.8 billion, up 2.19% from the prior year.
• Short term Debt rose to $4.5 billion in Q2 2026 per TEVA's latest filing, from $2.6 billion in the prior quarter.
• Across five years, Short term Debt topped out at $4.5 billion in Q2 2026 and bottomed at $24.0 million in Q3 2025.
• Historically, Short term Debt has averaged $1.9 billion across 5 years, with a median of $1.9 billion in 2023.
• The sharpest annual moves came in 2025 and 2026: Short term Debt tumbled 99.07% in 2025, then soared 869.83% in 2026.
• Over 5 years, Short term Debt stood at $2.1 billion in 2022, then retreated by 20.72% to $1.7 billion in 2023, then rose by 6.52% to $1.8 billion in 2024, then grew by 2.19% to $1.8 billion in 2025, then soared by 147.25% to $4.5 billion in 2026.
• According to Business Quant data, Short term Debt over the past three periods registered $4.5 billion, $2.6 billion, and $1.8 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.